Drug Target Review

JULY 12, 2023

These assays provide insights into the molecular mechanisms of disease biology and drug response, enabling the characterisation of gene expression profiles and deviations in diseased cells. Importantly, transcriptomics information shows that certain aspects of a disease change the gene expression profile.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Chemical Biology and Drug Design

FEBRUARY 7, 2024

Hydroxysafflor yellow A (HSYA), the main active component in the medical and edible dual-purpose plant safflower, has previously shown anti-inflammatory effects in various diseases. However, the specific impact of HSYA on OA remains unclear. Western blot was employed to investigate NF-κB transcription factors in chondrocyte metabolism.

Bioinformatics 100

Bioinformatics Treatment Production Disease 100

Broad Institute

AUGUST 7, 2024

At the Broad, he directs the Cancer Genome Computational Analysis Group , and he is a professor of pathology at Harvard Medical School and director of bioinformatics at Massachusetts General Hospital. Anna Greka ’s research focuses on fundamental mechanisms of cellular dysfunction in genetic diseases with a focus on membrane proteins.

Medical Schools 90

Medical Schools Hospitals Bioinformatics Vaccine 90

The Pharma Data

MAY 22, 2023

WHO launches global network to detect and prevent infectious disease threats WHO and partners are launching a global network to help protect people from infectious disease threats through the power of pathogen genomics. Diseases do not respect borders: a disease threat in one country is also a threat to others.

Disease 52

Disease Bioinformatics Virus Vaccine 52

Drug Target Review

MARCH 19, 2024

In other words, a disease state may cause a change in vitamin A levels rather than the vitamin A levels causing a change in disease state. Again, in this circumstance adding the vitamin will not help therapeutically with the disease state. Secondly, it’s difficult to separate causation from reverse causation.

Laboratories 105

Laboratories Bioinformatics International Research Laboratories 105

The Premier Consulting Blog

JUNE 18, 2023

One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases. However, with rare diseases there may be no available treatments that could serve as SoC or active control in a clinical trial and assigning patients to placebo may be unethical.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

The Open Targets Blog

OCTOBER 24, 2023

Amir Feizi is the Director of Bioinformatics at OMass Therapeutics, a spinout from Professor Dame Carol Robinson’s Laboratory at the University of Oxford. OMass Therapeutics is using a new technology platform to develop treatments for rare immunological and genetic diseases with high unmet patient needs.

Bioinformatics 62

Bioinformatics Packaging Pharmaceutical Companies Pharma Companies 62

The Pharma Data

NOVEMBER 15, 2020

” “We are committed to advancing innovative science and transformative medicines for people affected by different immune mediated diseases”, says James Sabry , Global Head, Roche Pharma Partnering. ” About Immune Mediated Diseases. A wide range of human diseases is driven by deregulated immune function.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

Broad Institute

APRIL 25, 2024

He started to imagine how the deadly and contagious disease, if confirmed, might spread to half the city’s population. Eight of the 20 patients died, but the spread of the disease in Nigeria stopped there. Blood and urine samples from the man were waiting for Happi in his lab. Happi felt chilled. They called the idea Sentinel.

Virus 132

Virus Hospitals Disease Government 132

Broad Institute

JULY 10, 2023

Credit: Allison Colorado, Broad Communications Arriving in the Bay Area after a childhood in increasingly diverse surroundings, Martin became acutely aware of health disparities and the profound differences in disease prevalence among different populations. I wanted to know how I could have any impact on studying genetic diversity.”

Disease 98

Disease Bioinformatics Medical Schools Research 98

Broad Institute

SEPTEMBER 30, 2024

Today, about a third of Broad’s Terra users are from the public health workforce; in the US, 76 state and local public health labs use the platform for preventing and monitoring infectious disease spread in their communities. This was true in the US and all the more in the Global South, where the burden of infectious disease is the highest.

Bioinformatics 101

Bioinformatics Disease Engineering Virus 101

PLOS: DNA Science

MAY 16, 2024

These factors are converging to enable both identification of novel infectious diseases as well as microbial resistance, before these threats can impact public health, write a team from the European Society for Clinical Microbiology and Infectious Diseases in Frontiers in Science. COVID clearly caught us off guard.

Virus 98

Virus DNA RNA Science 98

Drug Target Review

JANUARY 15, 2024

Cancer is a disease driven by variable genetic mutations. Overcoming this variability while sparing normal cells has stymied broad-acting therapeutic development. Our innate immune system evolved to clear genetically diverse pathogens and limit host toxicity, raising the possibility that it can produce similar effects in cancer.

Treatment 105

Treatment Immune Response Therapies Clinical Trials 105

The Open Targets Blog

AUGUST 13, 2024

It’s a fascinating study in collaboration, negotiation, influence and decision making as we aim to understand where we can build collaborative projects that will have impact in our ability to understand and treat disease –  projects such as Open-IBD. We are often treating the symptoms rather than the causes of disease.

Bioinformatics 70

Bioinformatics Disease Treatment Drugs 70

Drug Target Review

DECEMBER 6, 2024

Based in South Africa, she has worked extensively with international biotech companies, specialising in therapeutic development for aging-related diseases and complex conditions such as glioblastoma and Autosomal Dominant Polycystic Kidney Disease (ADPKD).

RNA 52

RNA Drugs Research Science 52

Drug Target Review

JULY 24, 2023

The study suggests that this regulatory system could be a potential target for future malaria treatments, offering hope for combatting this deadly disease that affects millions worldwide. The first identification was based on a bioinformatic analysis.

RNA 98

RNA Regulations Bioinformatics Laboratories 98

Elrig

APRIL 29, 2024

With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine. Bioinformatics is all about bringing together different areas of knowledge.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

The Open Targets Blog

FEBRUARY 29, 2024

  With a background in biochemistry and bioinformatics, Lucy was interested in exploring how bioinformatics was applied to real-world healthcare data. I just graduated with a degree in Bioinformatics, and I was interested to see how the skills I learned could be applied.

International 57

International Bioinformatics RNA Disease 57

Drug Target Review

JUNE 13, 2024

As well as this, the team highlight that the algorithm is independent and self-taught, determining which structural features are statistically most significant for assessing the severity of disease and had the largest impact on tumour recurrence. This study was published Nature Communications.

Bioinformatics 45

Bioinformatics Disease Laboratories Hospitals 45

Broad Institute

AUGUST 20, 2024

She’d always been interested in disease — why people got sick, why some illnesses could send you to a hospital while others could be treated at home. As she grew older, however, she realized she was more interested in learning about the roots of disease and the genes that caused them. Any errors are part of the code itself.

Science 69

Science Bioinformatics Disease Treatment 69

The Pharma Data

NOVEMBER 25, 2020

Egle has leveraged its unique bioinformatic and translational capabilities to successfully identify targets that will now be pursued under the terms of the alliance. Upon achievement of the target identification, Egle will receive an R&D milestone payment and investment from Takeda.

Research 52

Research Bioinformatics Pharmaceutical Companies Engineering 52

Codon

AUGUST 27, 2024

Doctors in training are told that when they hear hoofbeats, they should think horses, not zebras; rare diseases are the exception, not the rule. Sometimes, though, novel diseases do emerge, and as COVID-19 demonstrated, they can surprise us. This is the third essay of four in our pandemic mini-issue.

DNA 97

DNA Laboratories Hospitals Virus 97

DrugBaron

NOVEMBER 22, 2022

In 2015, Methuselah Health was founded to investigate the role of proteome instability during ageing, and the extent to which the instability of specific proteins might underlie development of age-related diseases – a concept that arose from the ground-breaking work of Professor Miro Radman (which DrugBaron highlighted previously).

Bioinformatics 100

Bioinformatics Regulations Molecular Biology Engineering 100

Broad Institute

AUGUST 29, 2016

Software engineering at Broad is about building creative solutions to catalog, manage, and analyze that dizzying volume of data, and make it available so that researchers around the world can do research that matters: understanding the genome and curing disease.

Bioinformatics 52

Bioinformatics Engineering Science Research 52

The Pharma Data

MARCH 2, 2021

Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. Obesity is a complex chronic disease that requires long-term management. It is among the leading risk factors for several cardio-metabolic diseases, such as heart disease, ischemic stroke, liver diseases incl.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

Vial

DECEMBER 5, 2023

Among others, NGS has led to the identification of disease-causing variants and novel drug targets and an improved understanding of complex biological events, e.g., the heterogeneity of tumors. 2022) recommend matching interventions to specific patient characteristics should be implemented early in the disease course. Fountzilas et al.

Clinical Trials 52

Clinical Trials Trials RNA Bioinformatics 52

Drug Target Review

SEPTEMBER 30, 2024

is its relation to the disease well figured out and validated? Dr Ofran received a PhD with distinction in Molecular Biophysics and Biomedical Informatics from Columbia University and was a professor of bioinformatics and molecular research at Bar-Ilan University. Is there still an unmet need? Can our technology solve the problem?

Bioinformatics 64

Bioinformatics Clinical Trials Clinical Development Treatment 64

DrugBank

FEBRUARY 12, 2025

In Silico Drug Repurposing Advances in bioinformatics and systems biology have fueled the rise of repurposing of in silico drugs. CMap utilizes gene expression profiles to connect drugs, genes, and diseases, enabling researchers to identify potential repurposing candidates based on their transcriptional signatures.

Cell Based Assays 52

Cell Based Assays Drugs Pharmacokinetics Disease 52

The Open Targets Blog

AUGUST 7, 2023

Following my interest in natural sciences, I moved to Novosibirsk (central Siberia) as soon as I was able, to study general biology, with a focus on statistical genetics and bioinformatics. I am an academic scientist through and through: I’ve been working in academia since university. What is on your to-do list in this new role?

Bioinformatics 52

Bioinformatics Disease Science 52

The Pharma Data

JANUARY 24, 2021

Professor of Medicine, Section of Infectious Diseases and Global Health and director of the Duchossois Family Institute at the University of Chicago, has joined its scientific advisory board. His research focuses on the role of the microbiome in immune defense and disease resistance. “We Diversigen, Inc.

Research 40

Research Bioinformatics Laboratories International 40

Broad Institute

AUGUST 4, 2022

By Tracy Hampton August 4, 2022 Credit: National Institutes of Allergy and Infectious Diseases, National Institutes of Health Colorized scanning electron micrograph of a B cell lymphocyte from a human donor.

Bioinformatics 52

Bioinformatics Medical Schools Hospitals Treatment 52

The Pharma Data

DECEMBER 27, 2020

28, 2020 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application (NDA) with the U.S. SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Food and Drug Administration (FDA).

FDA 52

FDA Bioinformatics Disease Production 52

The Open Targets Blog

APRIL 19, 2022

The Open Targets Platform integrates data from several sources, making connections between targets and diseases or phenotypes and providing context for these associations. Do the most relevant suggested connections between targets and diseases represent evidence? In the context of this post, we will focus on the first question.

Disease 52

Disease Bioinformatics FDA Production 52

The Pharma Data

DECEMBER 16, 2020

This includes Evotec’s data analysis platform “PanHunter”, a proprietary, integrated, user-centred bioinformatics platform which facilitates the analysis of PanOmics data integrated with other metadata sets.

Targeted Protein Degradation 40

Targeted Protein Degradation Bioinformatics Disease Drugs 40

The Pharma Data

JULY 27, 2021

The acquisition includes Teneobio’s proprietary bispecific and multispecific antibody technologies, which will enable significant acceleration and efficiency in the discovery and development of new molecules that have the potential to treat a wide range of important diseases across Amgen’s core therapeutic areas. Reese, M.D.,

Production 52

Production Clinical Trials Government Disease 52

The Pharma Data

SEPTEMBER 11, 2021

We look forward to working with Twist on molecular targets in a broad range of disease areas,” added Wood. Wood, Ph.D., Senior Corporate Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “We About Twist Bioscience Corporation.

DNA 52

DNA Bioinformatics Production Engineering 52

The Pharma Data

JANUARY 10, 2021

Maybe we need to treat the host rather than the cell or the disease. I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology.

Vaccine 52

Vaccine Disease Regulations Small Molecule 52